Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: a meta-analysis
Abstract Background Not all breast cancer (BC) patients can benefit from neoadjuvant therapy (NAT). A poor response may result in patients missing the best opportunity for treatment, ultimately leading to a poor prognosis. Thus, to identify an effective predictor that can assess and predict patient...
Saved in:
Main Authors: | Shuyi Niu, Tie Sun, Mozhi Wang, Litong Yao, Tianyi He, Yusong Wang, Hengjun Zhang, Xiang Li, Yingying Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-01-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-025-13526-0 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01) -
Breast Cancer: Neoadjuvant Chemotherapy
by: Barbara F. Shea, et al.
Published: (2015-05-01) -
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer
by: Jieun Park, et al.
Published: (2024-01-01) -
Does Apoptotic Index Predict the Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma?
by: Gokce ASKAN, et al.
Published: (2023-03-01) -
Research progress of artificial intelligence in evaluating the efficacy of neoadjuvant chemotherapy for breast cancer
by: Wei Wei, et al.
Published: (2024-09-01)